A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

Inclusion Criteria: * Aged ≥ 18 years. * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1 * Expected survival ≥ 6 months. * Histologically or cytologically confirmed local advanced/metastatic pancreas adenocarcinoma. * Documented mutation in germline BRCA1/2 or PALB2 that is predicted to be deleterious or suspected deleterious. * Adequate organ performance based on laboratory blood tests. * Presence of at least of one measurable lesion in agreement to RECIST criteria. * Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Patients who have received any chemotherapy for the treatment of pancreatic cancer prior to entering the study. * Previous treatment with any poly ADP-ribose polymerase (PARP) inhibitor. * Patients who have had radiotherapy or participated in another clinical trial with any investigational agents within 28 days of enrolment (Day 1 visit). * History of allergic reactions attributed to compounds of similar chemical or biologic composition to oxaliplatin, irinotecan, 5-Fluorouracil or other agents used in the study. * Previous treatment using CYP3A4 inducers within 3 weeks or inhibitors within 2 weeks of enrolment (Day 1 visit). * Patients with known or suspected brain metastasis. * Significant cardiovascular disease such as New York Heart Associate Class III/IV, cardiac failure, myocardial infarction, unstable arrhythmia, or evidence of ischemia on ECG within 6 months prior to enrolment. * Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication. * Patients with myelodysplastic syndrome/acute myeloid leukaemia. * Patients with second primary cancer except curatively treated in-situ cancer or slowly progressing malignancy. * Known active hepatitis B or C infection. * History of immunodeficiency (including HIV infection) or organ transplantation. * Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment.